Klingman & Associates’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.42M Buy
18,072
+280
+2% +$65.2K 0.21% 50
2025
Q4
$3.68M Buy
17,792
+191
+1% +$37.8K 0.18% 56
2025
Q3
$3.26M Sell
17,601
-657
-4% -$113K 0.16% 57
2025
Q2
$2.79M Buy
18,258
+1,274
+8% +$196K 0.15% 61
2025
Q1
$2.82M Buy
16,984
+2,005
+13% +$314K 0.17% 58
2024
Q4
$2.17M Sell
14,979
-336
-2% -$52.1K 0.13% 67
2024
Q3
$2.48M Buy
15,315
+214
+1% +$34.1K 0.15% 64
2024
Q2
$2.21M Sell
15,101
-578
-4% -$86K 0.15% 62
2024
Q1
$2.48M Sell
15,679
-149
-0.9% -$23.7K 0.17% 57
2023
Q4
$2.48M Sell
15,828
-31
-0.2% -$4.75K 0.18% 55
2023
Q3
$2.47M Sell
15,859
-282
-2% -$46.5K 0.2% 53
2023
Q2
$2.67M Sell
16,141
-1,150
-7% -$186K 0.22% 49
2023
Q1
$2.68M Sell
17,291
-224
-1% -$36.2K 0.23% 45
2022
Q4
$3.09M Buy
17,515
+254
+1% +$43.9K 0.27% 44
2022
Q3
$2.82M Sell
17,261
-356
-2% -$60.2K 0.28% 43
2022
Q2
$3.13M Sell
17,617
-144
-0.8% -$25.7K 0.31% 41
2022
Q1
$3.15M Buy
17,761
+4,716
+36% +$802K 0.27% 38
2021
Q4
$2.23M Buy
13,045
+150
+1% +$24.6K 0.19% 46
2021
Q3
$2.08M Buy
12,895
+130
+1% +$22.2K 0.19% 46
2021
Q2
$2.1M Sell
12,765
-1,527
-11% -$253K 0.2% 45
2021
Q1
$2.35M Buy
14,292
+1,304
+10% +$211K 0.24% 39
2020
Q4
$2.04M Buy
12,988
+2,700
+26% +$398K 0.24% 40
2020
Q3
$1.53M Buy
10,288
+1,125
+12% +$166K 0.21% 43
2020
Q2
$1.29M Buy
9,163
+300
+3% +$43.7K 0.2% 48
2020
Q1
$1.16M Buy
8,863
+804
+10% +$114K 0.24% 49
2019
Q4
$1.18M Buy
8,059
+26
+0.3% +$3.53K 0.19% 46
2019
Q3
$1.04M Sell
8,033
-34
-0.4% -$4.48K 0.19% 50
2019
Q2
$1.12M Buy
8,067
+34
+0.4% +$4.71K 0.21% 47
2019
Q1
$1.12M Buy
8,033
+100
+1% +$13.4K 0.22% 46
2018
Q4
$1.02M Hold
7,933
0.23% 44
2018
Q3
$1.1M Hold
7,933
0.22% 40
2018
Q2
$963K Sell
7,933
-84
-1% -$10.5K 0.21% 42
2018
Q1
$1.03M Sell
8,017
-7,913
-50% -$1.07M 0.23% 39
2017
Q4
$2.23M Sell
15,930
-10,777
-40% -$1.5M 0.49% 27
2017
Q3
$3.47M Buy
26,707
+22,512
+537% +$2.98M 0.85% 22
2017
Q2
$555K Buy
4,195
+556
+15% +$70.9K 0.15% 53
2017
Q1
$453K Sell
3,639
-32
-0.9% -$3.82K 0.13% 62
2016
Q4
$423K Sell
3,671
-175
-5% -$20.2K 0.13% 59
2016
Q3
$454K Buy
3,846
+175
+5% +$21.2K 0.14% 59
2016
Q2
$445K Hold
3,671
0.14% 57
2016
Q1
$397K Sell
3,671
-1,500
-29% -$155K 0.14% 67
2015
Q4
$531K Sell
5,171
-1,600
-24% -$161K 0.2% 59
2015
Q3
$632K Buy
6,771
+2,485
+58% +$240K 0.25% 49
2015
Q2
$418K Buy
4,286
+365
+9% +$36.6K 0.16% 57
2015
Q1
$394K Buy
3,921
+441
+13% +$44.8K 0.16% 58
2014
Q4
$363K Buy
+3,480
New +$367K 0.15% 63

Other funds holding JNJ

Klingman & Associates's JNJ Position: Q1 2026 in Review

Klingman & Associates increased its Johnson & Johnson (JNJ) stake by 1.6% in Q1 2026, buying an estimated $65.2K and bringing the position to 18,072 shares worth $4.42M. The position accounts for 0.21% of the portfolio, ranked #50.

Klingman & Associates first reported a position in JNJ in Q4 2014 and has held it in 46 quarters since. 4,615 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Klingman & Associates held 18,072 shares of Johnson & Johnson worth $4.42M as of Q1 2026.
  • Klingman & Associates bought 280 Johnson & Johnson shares in Q1 2026, an estimated $65.2K.
  • Johnson & Johnson made up 0.21% of Klingman & Associates's portfolio in Q1 2026, its #50 holding.
  • Klingman & Associates first reported a position in Johnson & Johnson in Q4 2014 and has held it in 46 quarters since.
  • 4,615 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Klingman & Associates's 13F filing for Q1 2026, filed 14 May 2026.